FDA: FDA Correspondence on EzriCare Artificial Tears Contamination

FDA: FDA Correspondence on EzriCare Artificial Tears Contamination

Regular price $89.00 USD
Regular price Sale price $89.00 USD
Sale Sold out
Request Content: Correspondence between FDA staff and representatives of Global Pharma Healthcare, EzriCare, or Delsam Pharma regarding the issues raised in FDA’s warning about EzriCare Artificial Tears contamination.
  • Status: Pending Fast-Track Request
  • Delivery: Approximately 1 to 2 weeks when the FOIA office is operating at regular capacity

NOTE: This document is not currently in our library. Upon purchase, we will request the document from the FDA FOIA office. Learn more about Fast-Track Requests here.

View full details